Pages that link to "Q22279758"

The following pages link to Kathleen I. Pritchard (Q22279758):

Displaying 39 items.

• Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review (Q33312762) (← links)
• Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review (Q33337684) (← links)
• Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer (Q33561953) (← links)
• A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12) (Q33618145) (← links)
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial (Q35119211) (← links)
• Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial (Q35155647) (← links)
• Review of the clinical studies using the 21-gene assay. (Q35584053) (← links)
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials (Q35740423) (← links)
• Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art (Q36278556) (← links)
• Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials (Q37015628) (← links)
• Cancer treatment-induced bone loss in breast and prostate cancer (Q37310013) (← links)
• Adjuvant targeted therapy in early breast cancer. (Q37376169) (← links)
• Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. (Q37640442) (← links)
• Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. (Q37671961) (← links)
• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents (Q37803154) (← links)
• Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer (Q37830371) (← links)
• Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy (Q38190425) (← links)
• Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors (Q42829932) (← links)
• Obesity and hormone therapy in breast cancer: an unfinished puzzle (Q43023356) (← links)
• Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial (Q43212287) (← links)
• Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients (Q43273251) (← links)
• (Q43273312) (redirect page) (← links)
• Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. (Q43290574) (← links)
• High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome (Q43815284) (← links)
• Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (Q45721339) (← links)
• Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (Q45754894) (← links)
• Combining endocrine agents with chemotherapy: which patients and what sequence? (Q46856126) (← links)
• Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14 (Q48593194) (← links)
• Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study (Q50937762) (← links)
• Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations (Q51364092) (← links)
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. (Q53158182) (← links)
• Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. (Q53224392) (← links)
• Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? (Q59622662) (← links)
• Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer (Q60595420) (← links)
• American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction (Q83917287) (← links)
• The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (Q90057116) (← links)
• Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer (Q92486395) (← links)
• Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study (Q96608943) (← links)
• Wikidata:WikiProject Medicine/Women scientists/3 (← links | edit)